1. Home
  2. CAPR vs WNC Comparison

CAPR vs WNC Comparison

Compare CAPR & WNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • WNC
  • Stock Information
  • Founded
  • CAPR 2005
  • WNC 1985
  • Country
  • CAPR United States
  • WNC United States
  • Employees
  • CAPR N/A
  • WNC N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • WNC Construction/Ag Equipment/Trucks
  • Sector
  • CAPR Health Care
  • WNC Industrials
  • Exchange
  • CAPR Nasdaq
  • WNC Nasdaq
  • Market Cap
  • CAPR 578.4M
  • WNC 526.5M
  • IPO Year
  • CAPR N/A
  • WNC 1991
  • Fundamental
  • Price
  • CAPR $15.00
  • WNC $12.13
  • Analyst Decision
  • CAPR Strong Buy
  • WNC Hold
  • Analyst Count
  • CAPR 7
  • WNC 1
  • Target Price
  • CAPR $39.29
  • WNC $18.00
  • AVG Volume (30 Days)
  • CAPR 902.1K
  • WNC 1.0M
  • Earning Date
  • CAPR 03-03-2025
  • WNC 01-29-2025
  • Dividend Yield
  • CAPR N/A
  • WNC 2.64%
  • EPS Growth
  • CAPR N/A
  • WNC N/A
  • EPS
  • CAPR N/A
  • WNC N/A
  • Revenue
  • CAPR $23,228,045.00
  • WNC $1,946,740,000.00
  • Revenue This Year
  • CAPR N/A
  • WNC $1.14
  • Revenue Next Year
  • CAPR $74.85
  • WNC $14.78
  • P/E Ratio
  • CAPR N/A
  • WNC N/A
  • Revenue Growth
  • CAPR 65.33
  • WNC N/A
  • 52 Week Low
  • CAPR $3.52
  • WNC $11.99
  • 52 Week High
  • CAPR $23.40
  • WNC $30.07
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 52.56
  • WNC 23.21
  • Support Level
  • CAPR $14.28
  • WNC $11.99
  • Resistance Level
  • CAPR $16.47
  • WNC $13.16
  • Average True Range (ATR)
  • CAPR 1.00
  • WNC 0.62
  • MACD
  • CAPR 0.07
  • WNC -0.10
  • Stochastic Oscillator
  • CAPR 55.05
  • WNC 3.68

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

About WNC Wabash National Corporation

Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The company's mission is to enable customers to succeed with breakthrough ideas and solutions that help them move everything from the first to the final mile. It designs and manufactures a diverse variety of products, including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.

Share on Social Networks: